CoChat

Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: A multinational, prospective, controlled, randomized trial

Open access
Thompson, Julie, Jones, Natasha, Al‐Khafaji, Ali, Malik, Shahid, Reich, David, Munoz, Santiago, MacNicholas, Ross, Hassanein, Tarek, Teperman, Lewis, Stein, Lance, Duarte‐Rojo, Andrés, Malik, Raza, Adhami, Talal, Asrani, Sumeet, Shah, Nikunj, Gaglio, Paul, Duddempudi, Anupama, Borg, Brian, Jalan, Rajiv, Brown, Robert, Patton, Heather, Satoskar, Rohit, Rossi, Simona, Parikh, Amay, ElSharkawy, Ahmed, Mantry, Parvez, Sher, Linda, Wolf, David, Hart, Marquis, Landis, Charles, Wigg, Alan, Habib, Shahid, McCaughan, Geoffrey, Colquhoun, Steven, Henry, Alyssa, Bedard, Patricia, Landeen, Lee, Millis, Michael, Ashley, Robert, Frank, William, Henry, Andrew, Stange, Jan, Subramanian, Ram, on behalf of the VTI‐208 Study Group · 2018 · Liver Transplantation
Cited by 151

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Severe alcoholic hepatitis (sAH) is associated with a poor prognosis. There is no proven effective treatment for sAH, which is why early transplantation has been increasingly discussed. Hepatoblastoma‐derived C3A cells express anti‐inflammatory proteins and growth factors and were tested in an extracorporeal cellular therapy (ELAD) study to establish their effect on survival for subjects with sAH. Adults with sAH, bilirubin ≥8 mg/dL, Maddrey's discriminant function ≥ 32, and Model for End‐Stage Liver Disease (MELD) score ≤ 35 were randomized to receive standard of care (SOC) only or 3‐5 days of continuous ELAD treatment plus SOC. After a minimum follow‐up of 91 days, overall survival (OS) was assessed by using a Kaplan‐Meier survival analysis. A total of 203 subjects were enrolled (96 ELAD and 107 SOC) at 40 sites worldwide. Comparison of baseline characteristics showed no significant differences between groups and within subgroups. There was no significant difference in serious adverse events between the 2 groups. In an analysis of the intent‐to‐treat population, there was no difference in OS (51.0% versus 49.5%). The study failed its primary and secondary end point in a population with sAH and with a MELD ranging from 18 to 35 and no upper age limit. In the prespecified analysis of subjects with MELD < 28 (n = 120), ELAD was associated with a trend toward higher OS at 91 days (68.6% versus 53.6%; P = .08). Regression analysis identified high creatinine and international normalized ratio, but not bilirubin, as the MELD components predicting negative outcomes with ELAD. A new trial investigating a potential benefit of ELAD in younger subjects with sufficient renal function and less severe coagulopathy has been initiated. Liver Transplantation 24 380–393 2018 AASLD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/lt.24986

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 151

Metadata

Authors
Thompson, J., Jones, N., Al‐Khafaji, A., Malik, S., Reich, D., Munoz, S., MacNicholas, R., Hassanein, T., Teperman, L., Stein, L., Duarte‐Rojo, A., Malik, R., Adhami, T., Asrani, S., Shah, N., Gaglio, P., Duddempudi, A., Borg, B., Jalan, R., Brown, R., Patton, H., Satoskar, R., Rossi, S., Parikh, A., ElSharkawy, A., Mantry, P., Sher, L., Wolf, D., Hart, M., Landis, C., Wigg, A., Habib, S., McCaughan, G., Colquhoun, S., Henry, A., Bedard, P., Landeen, L., Millis, M., Ashley, R., Frank, W., Henry, A., Stange, J., Subramanian, R., & on behalf of the VTI‐208 Study Group
Venue
Liver Transplantation
Published
2018-02-23
Volume
24
Issue
3
Pages
380-393
ISSN
  • 1527-6465 (ISSN-L)
  • 1527-6473
OpenAlex
W2768152453
Cited by
151
References
2
FWCI
8.93
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.